BRCA1 and neoplasm: The possible mechanism of action of PARP inhibitors in the TME of BRCA1-mutated TNBC was elucidated by Pantelidou et al. The authors demonstrated that the PARP inhibitor olaparib induced CD8+ T cell infiltration and activation through cGAS/STING pathway in tumor cells [118].